《復牌》北海康成(01228.HK)向百洋醫藥發新股集資1億 訂商業服務協議
北海康成-B(01228.HK)公布,向百洋醫藥股份(301015.SZ)發行7,497萬股新股,每股作價1.34元,較停牌前收報折讓19.76%。集資總額1億元,所得淨額9,866萬元,擬用於商業化產品的研發;營銷及推廣活動;償還貸款融資;及日常營運。完成後,百洋醫藥將持有公司股本14.99%,後者已表示其無意於三年內收購公司任何控股股份。
同時,公司兩家附屬與百洋醫藥股份附屬百洋附屬訂立一份戰略合作及獨家商業服務協議。據此,相關附屬同意委任百洋附屬為獨家合同銷售組織,於內地、香港及澳門推廣集團的若干產品。
公司股份已申請周三(13日)恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.